|
Canada-ON-CAMPBELLFORD Azienda Directories
|
Azienda News:
- ENJAYMO® (sutimlimab-jome) | Cold Agglutinin Disease Treatment
ENJAYMO is the first and only FDA-approved treatment for people with cold agglutinin disease (CAD) to help decrease the need for red blood cell transfusion For U S Residents Only ENJAYMO Patient Solutions (1-833-223-2428) Prescribing Info Medication Guide HCP Website
- ENJAYMO® (sutimlimab-jome) | What is ENJAYMO?
Serious Infections: ENJAYMO is a prescription medicine that affects your immune system ENJAYMO may lower the ability of your immune system to fight infections ENJAYMO increases your chance of getting serious infections including those caused by encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B
- HIGHLIGHTS OF PRESCRIBING INFORMATION - enjaymo. com
The recommended dosage of ENJAYMO for patients with CAD is based on body weight For patients weighing 39 kg to less than 75 kg, the recommended dose is 6,500 mg and for patients weighing 75 kg or more, the recommended dose is 7,500 mg Administer ENJAYMO intravenously weekly for the first two weeks, with administration every two
- ENJAYMO® (sutimlimab-jome) | What is Cold Agglutinin Disease?
ENJAYMO may lower the ability of your immune system to fight infections ENJAYMO increases your chance of getting serious infections including those caused by encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B These serious infections may quickly become life-threatening or cause
- ENJAYMO® (sutimlimab-jome) | Resources
Serious Infections: ENJAYMO is a prescription medicine that affects your immune system ENJAYMO may lower the ability of your immune system to fight infections ENJAYMO increases your chance of getting serious infections including those caused by encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B
- ENJAYMO® (sutimlimab-jome) | How ENJAYMO Can Help Treat CAD
ENJAYMO is designed to help stop hemolysis before it starts, preventing red blood cells from being destroyed For U S Residents Only ENJAYMO Patient Solutions (1-833-223-2428) Prescribing Info Medication Guide HCP Website About Enjaymo What is Enjaymo How Enjaymo works Safety Side Effects
- ENJAYMO® (sutimlimab-jome) | ENJAYMO Dosing
The ENJAYMO dosing schedule is designed to provide a continuous level of medicine ENJAYMO is given as an intravenous (IV) infusion weekly for the first 2 weeks, and then every 2 weeks thereafter Your dose of ENJAYMO (either 6 5 g or 7 5 g) is based on your body weight, which your doctor will determine for you
- ENJAYMO® (sutimlimab-jome) | Patient Solutions
The ENJAYMO Patient Solutions Copay Program (the “Program”) is not valid for prescriptions covered, in whole or in part, under Medicare, Medicaid, VA, DoD, TRICARE® or similar federal or state programs, including any state pharmaceutical assistance programs The Program is not valid where prohibited by law, and savings may vary depending
- ENJAYMO® (sutimlimab-jome) | FAQ
ENJAYMO may lower the ability of your immune system to fight infections ENJAYMO increases your chance of getting serious infections including those caused by encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B These serious infections may quickly become life-threatening or cause
- ENJAYMO is the first and only FDA-approved treatment for people with . . .
ENJAYMO® is a prescription medicine used to treat the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD) It is not known if ENJAYMO is safe and effective in children IMPORTANT SAFETY INFORMATION Do not receive ENJAYMO if you are allergic to sutimlimab-jome or any of the ingredients in ENJAYMO
|
|